ϳԹ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ϳԹ News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Nov 15 2021

Full Issue

Effectiveness Of Covid Vaccines Over Time Examined

Scientists compile evidence on the waning effectiveness of covid vaccines and which ones generate the most antibodies.

As tens of millions of eligible people in the United States consider signing up for a COVID-19 booster shot, a growing body of early global research shows that the vaccines authorized in the United States remain highly protective against the disease’s worst outcomes over time, with some exceptions among older people and those with weakened immune systems. But although the vaccines’ effectiveness against severe disease and hospitalization has mostly held steady, even through the summer surge of the highly transmissible delta variant, a number of published studies show that their protection against infection, with or without symptoms, has fallen. (Schoenfeld Walker and Holder, 11/14)

Pfizer Inc. and BioNTech SE’s Covid-19 shot yielded the strongest immune response among four vaccines tested in a study, which found people getting Sinopharm’s inoculation may be particularly susceptible to a breakthrough coronavirus infection. Levels of protective antibodies to the part of the coronavirus that SARS-CoV-2 uses to infect human cells varied widely across each of the four vaccine groups. “Relatively low” antibody concentrations were stimulated by the Sinopharm and Sputnik V vaccines, intermediate levels for the AstraZeneca Plc vaccine, and the highest values for the Pfizer-BioNTech vaccine, a study in the journal Cell Host and Microbe showed. (Gale, 11/15)

Some 71 million Americans have been vaccinated with the Moderna vaccine. The company has seen its stock price soar. But last week, Moderna announced that the U.S. Food and Drug Administration would take more time to decide whether the company’s two-dose vaccine could be used on children aged 12 to 17 after studies showed the vaccine resulted in a higher incidence of myocarditis, or inflammation of the heart, in males. (Therese Raphael and Sam Fazeli, 11/15)

The United States had administered 440,559,613 doses of COVID-19 vaccines in the country as of Sunday morning, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 439,034,461 vaccine doses the CDC said had gone into arms by Nov. 13. The agency said 226,607,653 people had received at least one dose while 195,120,470 people had been fully vaccinated as of 6:00 a.m. ET on Sunday. (11/14)

On the vaccine rollout for younger kids —

D.C. Health said it did not have data available on how many 5-to-11-year-olds in all had received their first dose across the city. Two hundred and fifty doses were available at each clinic, according to D.C. Health. But on Tuesday in Mount Pleasant, a large crowd of parents lined up outside the Bancroft gymnasium doors, some of whom would later have to be turned away by school staff as the clinic ran low on doses. (Asbury, 11/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ϳԹ
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF